A Trial of AK112 (PD1/VEGF Bispecific) in Combination With Chemotherapy in Patients With NSCLC

Phase 2 Active not recruiting 265 enrolled Akeso

RandomizedParallel-groupOpen-labelTreatment

Summary

This is a phase II study. All patients are stage IIIB/C or IV non-small cell lung cancer(NSCLC), Eastern Cooperative Oncology Group (ECOG) performance status 0-1. The purpose of this study is to evaluate the efficacy and safety of AK112 in combination with chemotherapy in patients with NSCLC.

Timeline

Start: 2021-02-01
Primary completion: 2026-07
Completion: 2026-12

Publications

Zhao Y, Chen G, Chen J, Zhuang L, Du Y, Yu Q, Zhuang W, Zhao Y, Zhou M, Zhang W, Zhang Y, Wan Y, Li W, Song W, Wang ZM, Li B, Xia M, Yang Y, Fang W, Huang Y, Zhang L. AK112, a novel PD-1/VEGF bispecific antibody, in combination with chemotherapy in patients with advanced non-small cell lung cancer (NSCLC): an open-label, multicenter, phase II trial. EClinicalMedicine. 2023 Aug 3;62:102106. doi: 10.1016/j.eclinm.2023.102106. eCollection 2023 Aug.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Carboplatin	Small molecule	5 unknown	Intravenous
Subject	Docetaxel	Small molecule	75 mg/m2	Intravenous
Subject	Ivonescimab	Monoclonal antibody	10 mg/kg	Intravenous
Subject	Ivonescimab	Monoclonal antibody	20 mg/kg	Intravenous
Subject	Paclitaxel	Small molecule	175 mg/m2	Intravenous
Subject	Pemetrexed	Small molecule	500 mg/m2	Intravenous

A Trial of AK112 (PD1/VEGF Bispecific) in Combination With Chemotherapy in Patients With NSCLC

Summary

Timeline

Publications

Drugs

Indications